Phase 2 Study of ZW25 Plus First-line Combination Chemotherapy in HER2-Expressing Gastroesophageal Adenocarcinoma (GEA), Biliary Tract Cancer (BTC), And Colorectal Cancer (CRC)
To determine if the experimental study drug ZW25 is safe and effective in the treatment of HER2-expressing GI cancers
DiagnosisPatient who have been diagnosed with one of the following human epidermal growth factor receptor 2 (HER2)-expressing gastrointestinal cancers • Gastroesophageal adenocarcinoma • Biliary tract cancer • Colorectal cancer
Patients with unresectable, locally advanced, recurrent or metastatic HER2-expressing GEA, BTC, or CRC
Patients must sign an approved informed consent and authorization permitting release of personal health information.
First-line, study to investigate the safety, tolerability, and antitumor activity of ZW25 plus standard 1st line combination chemotherapy regimens of physician choice
For more information, visit Clinicaltrials.gov